Business Context and Reporting Period
Akebia Therapeutics, Inc. (AKBA) filed a Current Report on Form 8-K dated October 15, 2024. The filing reports the entry into a material definitive agreement regarding the manufacturing of its drug product, vadadustat.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a disclosure of a contractual amendment only.
Material Changes
- Agreement Extension: The Company amended its 2021 Supply Agreement with STA Pharmaceutical Hong Kong Limited, extending the term until January 1, 2032.
- Pricing Structure: The amendment modifies the volume-based pricing structure for the vadadustat drug product.
- Other Provisions: Certain other provisions related to the product under the Supply Agreement were amended.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors. The full text of the Amendment is expected to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2024.
Investor Verification Checklist
- Verify the specific details of the new volume-based pricing structure in the upcoming Form 10-Q exhibit.
- Confirm the impact of the extended term (through 2032) on long-term manufacturing costs and supply chain stability.
- Review the "other provisions" amended to assess any changes in liability or operational obligations.